HKSE:02315 (China)
Â
Class H
HK$
5.84
(+1.39%)
Nov 29
Business Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd
ISIN : CNE100005D27
Share Class Description:
HKSE:02315: Class HCompare
Compare
Traded in other countries / regions
02315.Hong KongI54.Germany IPO Date
2022-09-01Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.68 | |||||
| Equity-to-Asset | 0.3 | |||||
| Debt-to-Equity | 0.78 | |||||
| Debt-to-EBITDA | -4.29 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -0.23 | |||||
| Beneish M-Score | -2.79 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 37.5 | |||||
| 3-Year EBITDA Growth Rate | 39.7 | |||||
| 3-Year EPS without NRI Growth Rate | -0.1 | |||||
| 3-Year FCF Growth Rate | 29.4 | |||||
| 3-Year Book Growth Rate | -20.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 24.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.26 | |||||
| 9-Day RSI | 39.64 | |||||
| 14-Day RSI | 40.76 | |||||
| 6-1 Month Momentum % | -26.78 | |||||
| 12-1 Month Momentum % | -43.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.34 | |||||
| Quick Ratio | 1.17 | |||||
| Cash Ratio | 0.68 | |||||
| Days Inventory | 148.85 | |||||
| Days Sales Outstanding | 67.16 | |||||
| Days Payable | 227.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | -4.89 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 71.95 | |||||
| Operating Margin % | -18.62 | |||||
| Net Margin % | -30.6 | |||||
| FCF Margin % | -11.13 | |||||
| ROE % | -29.47 | |||||
| ROA % | -9.64 | |||||
| ROIC % | -7.41 | |||||
| ROC (Joel Greenblatt) % | -8.88 | |||||
| ROCE % | -6.86 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 24.72 | |||||
| PS Ratio | 2.66 | |||||
| PB Ratio | 2.92 | |||||
| Price-to-Tangible-Book | 3.03 | |||||
| EV-to-EBIT | -17.25 | |||||
| EV-to-Forward-EBIT | -170.68 | |||||
| EV-to-EBITDA | -17.25 | |||||
| EV-to-Revenue | 2.87 | |||||
| EV-to-Forward-Revenue | 7.55 | |||||
| EV-to-FCF | -27.18 | |||||
| Earnings Yield (Greenblatt) % | -5.8 | |||||
| FCF Yield % | -4.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biocytogen Pharmaceuticals (Beijing) Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 868.577 | ||
| EPS (TTM) (HK$) | -0.665 | ||
| Beta | 0 | ||
| Volatility % | 38.41 | ||
| 14-Day RSI | 40.76 | ||
| 14-Day ATR (HK$) | 0.420258 | ||
| 20-Day SMA (HK$) | 5.9585 | ||
| 12-1 Month Momentum % | -43.12 | ||
| 52-Week Range (HK$) | 5.6 - 12.8 | ||
| Shares Outstanding (Mil) | 398.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biocytogen Pharmaceuticals (Beijing) Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biocytogen Pharmaceuticals (Beijing) Co Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biocytogen Pharmaceuticals (Beijing) Co Ltd Frequently Asked Questions
What is Biocytogen Pharmaceuticals (Beijing) Co Ltd(HKSE:02315)'s stock price today?
The current price of HKSE:02315 is HK$5.84. The 52 week high of HKSE:02315 is HK$12.80 and 52 week low is HK$5.60.
When is next earnings date of Biocytogen Pharmaceuticals (Beijing) Co Ltd(HKSE:02315)?
The next earnings date of Biocytogen Pharmaceuticals (Beijing) Co Ltd(HKSE:02315) is .
Does Biocytogen Pharmaceuticals (Beijing) Co Ltd(HKSE:02315) pay dividends? If so, how much?
Biocytogen Pharmaceuticals (Beijing) Co Ltd(HKSE:02315) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers